Bousmekine






Names

    • Bousmekine

Attributes

  • Canonical SMILES

    CC(C[C@H]4C=C[C@@]3(CC)CC(C(OC)=O)=C2NC1=CC(OC)=CC=C1[C@@]52[C@H]3N4CC5)=O

  • InChI

    InChI=1S/C25H30N2O4/c1-5-24-9-8-16(12-15(2)28)27-11-10-25(23(24)27)19-7-6-17(30-3)13-20(19)26-21(25)18(14-24)22(29)31-4/h6-9,13,16,23,26H,5,10-12,14H2,1-4H3/t16-,23+,24+,25+/m1/s1

  • Molecule Class: Alkaloids
  • TPSA: 67.87
  • #RotBonds: 5
  • MW: 422.5250000000002
  • HBD: 1
  • HBA: 6
  • logP: 3.5775000000000023
  • Chemical Formula: C25H30N2O4


Species

    Species Place of Collection NCBI Taxonomy Voucher Specimen
    T. divaricata China, Japan, Thailand, Bangladesh, Vienna 52861 BBP0671

External Databases


References

  • Taberdines L and M, two new alkaloids from Tabernaemontana divaricata. Nat Prod Res, 2022 (PMID 34933610).

Compound-Protein Relationships

  • No relationship found

Compound Activities

    • Cytotoxicity

Predicted NMR Spectral Data


Predicted MS Fragmentation Pattern

    N.B.: It is recommended to zoom in on a specific area of an MS plot before hovering on a peak.

Predicted ADMET Properties

    Property Model Name Predicted Value
    Absorption Caco-2 (logPaap) -4.9
    Human Oral Bioavailability 20% Bioavailable
    Human Intestinal Absorption Absorbed
    Madin-Darby Canine Kidney -4.76
    Human Oral Bioavailability 50% Non-Bioavailable
    P-Glycoprotein Inhibitor Non-Inhibitor
    P-Glycoprotein Substrate Substrate
    Skin Permeability -2.73
    Distribution Blood-Brain Barrier (Central Nervous System) -2.65
    Blood-Brain Barrier Penetrable
    Fraction Unbound (Human) 0.96
    Plasma Protein Binding 60.21
    Steady State Volume of Distribution 2.9
    Metabolism Breast Cancer Resistance Protein Non-Inhibitor
    CYP 1A2 Inhibitor Non-Inhibitor
    CYP 1A2 substrate Substrate
    CYP 2C19 Inhibitor Inhibitor
    CYP 2C19 substrate Substrate
    CYP 2C9 Inhibitor Non-Inhibitor
    CYP 2C9 Substrate Non-Substrate
    CYP 2D6 Inhibitor Inhibitor
    CYP 2D6 Substrate Non-Substrate
    CYP 3A4 Inhibitor Inhibitor
    CYP 3A4 Substrate Substrate
    OATP1B1 Non-Inhibitor
    OATP1B3 Non-Inhibitor
    Excretion Clearance 8.17
    Organic Cation Transporter 2 Non-Inhibitor
    Half-Life of Drug Half-Life < 3hs
    Toxicity AMES Mutagenesis Safe
    Avian Safe
    Bee Toxic
    Bioconcentration Factor -0.26
    Biodegradation Safe
    Carcinogenesis Safe
    Crustacean Toxic
    Liver Injury I Safe
    Eye Corrosion Safe
    Eye irritation Safe
    Maximum Tolerated Dose -0.5
    Liver Injury II Toxic
    hERG Blockers Toxic
    Daphnia Maga 6.31
    Micronucleos Toxic
    NR-AhR Safe
    NR-AR Safe
    NR-AR-LBD Safe
    NR-Aromatase Safe
    NR-ER Safe
    NR-ER-LBD Safe
    NR-GR Safe
    NR-PPAR-gamma Safe
    NR-TR Toxic
    T. Pyriformis -87.06
    Rat (Acute) 3.06
    Rat (Chronic Oral) 2.09
    Fathead Minnow 4.05
    Respiratory Disease Toxic
    Skin Sensitisation Safe
    SR-ATAD5 Toxic
    SR-ARE Toxic
    SR-HSE Safe
    SR-MMP Safe
    SR-p53 Safe
    General Properties Boiling Point 457.31
    Hydration Free Energy -2.9
    Log(D) at pH=7.4 3.12
    Log(P) 3.13
    Log S -3.38
    Log(Vapor Pressure) -8.38
    Melting Point 170.4
    pKa Acid 8.12
    pKa Basic 6.07